Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Chief Operating Officer | June 09, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date June 09, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 700,000 |
Ending reported balance
After 2026-06-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-06-09 · Exercise / conversion · Acquired 3,000 · Balance 703,000 Row 2 · 2026-06-09 · Sale · Disposed 3,000 · Balance 700,000 Row 3 · 2026-06-10 · Exercise / conversion · Acquired 5,000 · Balance 705,000 Row 4 · 2026-06-10 · Sale · Disposed 5,000 · Balance 700,000 F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Row 5 · 2026-06-18 · Exercise / conversion · Acquired 3,000 · Balance 703,000 Row 6 · 2026-06-18 · Sale · Disposed 3,000 · Balance 700,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-10-31 | Direct | 835,701 |
Reported balance
After 2026-06-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-09 · Exercise / conversion · Disposed 3,000 · Balance 835,701 F2: These options are vested in full. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-10-31 | Direct | 830,701 |
Reported balance
After 2026-06-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-10 · Exercise / conversion · Disposed 5,000 · Balance 830,701 F2: These options are vested in full. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-10-31 | Direct | 827,701 |
Reported balance
After 2026-06-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-18 · Exercise / conversion · Disposed 3,000 · Balance 827,701 F2: These options are vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2: These options are vested in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2025 Filed Apr 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-25-015712 · form4.xml · derivative · entry 6 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,015,115 Underlying: Common Stock · 150,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
| March 27, 2025 Filed Apr 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 150,000 | $0.75 | $112,500.00 |
DisclosureSEC source: 0001140361-25-015712 · form4.xml · nonDerivative · entry 3 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2025 Filed Apr 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-25-015712 · form4.xml · derivative · entry 5 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165,115 Underlying: Common Stock · 200,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
| March 26, 2025 Filed Apr 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 200,000 | $0.75 | $150,000.00 |
DisclosureSEC source: 0001140361-25-015712 · form4.xml · nonDerivative · entry 2 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2025 Filed Apr 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-25-015712 · form4.xml · derivative · entry 4 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,365,115 Underlying: Common Stock · 300,000 shares Expires 2030-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
| March 24, 2025 Filed Apr 25, 2025 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 300,000 | $0.75 | $225,000.00 |
DisclosureSEC source: 0001140361-25-015712 · form4.xml · nonDerivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 12, 2025 00:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $10.32 | $0.00 |
DisclosureSEC source: 0001140361-25-008167 · form4.xml · derivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-03-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 300,000 shares of the Issuer's common stock and will vest in 48 equal monthly installments through March 7, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:49 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,665,115 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-23-054520 · form4.xml · derivative · entry 1 Ye Weiguo · CIK 0001985496 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,665,115 Underlying: Common Stock · 1,665,115 shares Expires 2030-10-31 F1 · derivative.exercise_price: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F1 · derivative.exercise_date: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F2 · derivative.exercise_date: These options are vested in full. F1 · derivative.expiration_date: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.